Adenoviral Transduction of Human Acid Sphingomyelinase into Neo-Angiogenic Endothelium Radiosensitizes Tumor Cure

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Stancevic, Branka ^a   Varda Bloom, Nira ^a   Cheng, Jin ^a   Fuller, John D ^a   Rotolo, Jimmy A ^a   García Barros, Mónica ^a   Feldman, Regina ^a   Rao, Shyam ^a   Weichselbaum, Ralph R ^b   Harats, Dror ^c   Haimovitz Friedman, Adriana ^a   Fuks, Zvi ^a   Sadelain, Michel ^a   Kolesnick, Richard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Vascular Biogenics Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PREPROENDOTHELIN 1; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CLONE; CONTROLLED STUDY; FIBROSARCOMA; GENE OVEREXPRESSION; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR VASCULARIZATION; UPREGULATION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; ENDOTHELIUM, VASCULAR; FIBROSARCOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 84880983166     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069025     Document Type: Article

References (55)

1. Hall EJ, Giaccia AJ (2006) In:McAllister L, Bierig L, Barrett K, editors. Radiobiology for the Radiologist. Sixth Edition ed. Philadelphia: Lippincott, Williams & Wilkins. 378-397.
2. Hoppe RT, Phillips TL, Roach M (2010) Leibel and Phillips textbook of radiation oncology; Saunders E, editor. Philadelphia, PA. 40-54.
3. Leibel SA, Ling CC, Kutcher GJ, Mohan R, Cordon-Cordo C, et al. (1991) The biological basis for conformal three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys 21: 805-811.
4. Okunieff P, Morgan D, Niemierko A, Suit HD, (1995) Radiation dose-response of human tumors. Int J Rad Oncol Biol Phys 32: 1227-1237.
5. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, et al. (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71: 484-490.
6. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, et al. (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59: 145-170.
7. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, et al. (2009) Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther 9: 621-635.
8. Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, et al. (2011) Predictors of Local Control After Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases. Int J Rad Oncol Biol Phys 79: 1151-1157.
9. Brown JM, Koong AC, (2008) High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology? Int J Rad Oncol Biol Phys 71: 324-325.
10. Fowler JF, Tomé WA, Fenwick JD, Mehta MP, (2004) A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60: 1241-1256.
11. Fuks Z, Kolesnick R, (2005) Engaging the vascular component of the tumor response. Cancer Cell 8: 89-91.
12. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, et al. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159.
13. Truman JP, Garcia-Barros M, Kaag M, Hambardzumyan D, Stancevic B, et al. (2010) Endothelial Membrane Remodeling is Obligate for Anti-angiogenic Radiosensitization during Tumor Radiosurgery. PLoS ONE 5.
14. Garcia-Barros M, Thin TH, Cordon-Cordo C, Haimovitz-Friedman A, Fuks Z, et al. (2010) Impact of Stromal Sensitivity on Radiation Response of Tumors Implanted in SCID Hosts Revisited. Cancer Res 70: 8179-8186.
15. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, et al. (1996) Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86: 189-199.
16. Marathe S, Schissel S, Yellin M, Beatini N, Mintzer R, et al. (1998) Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 273: 4081-4088.
17. Stancevic B, Kolesnick R, (2010) Ceramide-rich platforms in transmembrane signaling. FEBS Lett 584: 1728-1740.
18. Rotolo J, Stancevic B, Zhang J, Hua G, Fuller J, et al. (2012) Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J Clin Invest 122: 1786-1790.
19. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, et al. (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278: 7520-7530.
20. Varda-Bloom N, Hodish I, Shaish A, Greenberger S, Tal R, et al. (2008) Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK. Pathobiology 75: 346-355.
21. Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, et al. (2001) Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 8: 819-827.
22. Smith EL, Schuchman EH, (2008) Acid Sphingomyelinase Overexpression Enhances the Antineoplastic Effects of Irradiation In Vitro and In Vivo. Mol Ther 16: 1565-1571.
23. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I, (1998) The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 273: 18250-18259.
24. Moeller BJ, Cao Y, Li CY, Dewhirst MW, (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
25. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, et al. (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297.
26. Pena LA, Fuks Z, Kolesnick RN, (2000) Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 60: 321-327.
27. Withers HR, Elkind MM, (1970) Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol Relat Stud Phys Chem Med 17: 261-267.
28. Rotolo JA, Maj JG, Feldman R, Ren D, Haimovitz-Friedman A, et al. (2008) Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa. Int J Radiat Oncol Biol Phys 70: 804-815.
29. Rönicke V, Risau W, Breier G, (1996) Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res 79: 277-285.
30. Kappel A, Rönicke V, Damert A, Flamme I, Risau W, et al. (1999) Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 93: 4284-4292.
31. Moolten FL, Wells JM, (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300.
32. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, et al. (1991) Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3: 608-614.
33. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, et al. (2000) Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2: 114-120.
34. Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, et al. (2000) HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 7: 1483-1490.
35. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, et al. (1995) Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Rad Oncol Biol Phys 33: 861-868.
36. Kim JH, Kim SH, Brown SL, Freytag SO, (1994) Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 54: 6053-6056.
37. Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, et al. (2006) Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 24: 2052-2058.
38. Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, et al. (2007) A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 14: 885-893.
39. Triozzi P, Brenner A, Giles FJ, Cohen YC, Breitbart E, et al. (2010) A Phase I trial of VB-111, a tissue and condition specific vascular disruptive anti-angiogenic agent, based on novel Vascular Targeting System, VTS, for treatment of patients with advanced metastatic cancer. Washington, D.C.
40. Cox BW, Jackson A, Hunt M, Bilsky M, Yamada Y, (2012) Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Rad Oncol Biol Phys 83: e661-667.
41. Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, et al. (2011) Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 12: 3368.
42. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, et al. (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37: 4078-4101.
43. Spalding AC, Lawrence TS, (2006) New and emerging radiosensitizers and radioprotectors. Cancer Invest 24: 444-456.
44. Bentzen SM, Harari PM, Bernier J, (2007) Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4: 172-180.
45. Brown JM, (2007) Tumor hypoxia in cancer therapy. Methods Enzymol 435: 297-321.
46. Page P, Yang LX, (2010) Novel chemoradiosensitizers for cancer therapy. Anticancer Res 30: 3675-3682.
47. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, Witte L, Fuks Z, (1991) Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 51: 2552-2558.
48. Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, et al. (2001) Ceramide enables fas to cap and kill. J Biol Chem 276: 23954-23961.
49. Rotolo JA, Zhang J, Donepudi M, Lee H, Fuks Z, et al. (2005) Caspase-dependent and-independent activation of acid sphingomyelinase signaling. J Biol Chem 280: 26425-26434.
50. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, et al. (1999) Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59: 5194-5201.
51. Schissel SL, Schuchman EH, Williams KJ, Tabas I, (1996) Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 271: 18431-18436.
52. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL, (2000) A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7: 1034-1038.
53. Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, et al. (1995) Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet 10: 288-293.
54. Kim JH, Alfieri AA, Kim SH, Young CW, (1986) Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 46: 1120-1123.
55. Albright N, (1987) Computer programs for the analysis of cellular survival data. Radiat Res 112: 331-340.